Aetiology and consequences of the metabolic syndrome

European Heart Journal, Supplement

Volumn 7, Issue D, 2005, Pages

  Standl, Eberhard ^a  

^a Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; FATTY ACID; NITRIC OXIDE SYNTHASE; VERY LOW DENSITY LIPOPROTEIN;

BODY FAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK FACTOR; WAIST CIRCUMFERENCE;

EID: 20744439397     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui023     Document Type: Conference Paper

References (17)

1. Deen D. Metabolic syndrome: time for action. Am Fam Physician 2004;69:2875-2882.
2. Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med 2003;4:S11-S18.
3. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991;337:382-386.
4. Nielsen S, Guo Z, Johnson CM et al. Splanchnic lipolysis in human obesity. J Clin Invest 2004;113:1582-1588.
5. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003;11: 1278-1289.
6. Hattori Y, Suzuki M, Hattori S et al. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003;46:1543-1549.
7. Ninomiya JK, L'Italien G, Criqui MH et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109:42-46.
8. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
9. Bonora E, Targher G, Formentini F et al. The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona diabetes complications study. Diabet Med 2002;21:52.
10. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
11. Ridker PM, Buring JE, Cook NR et al. C-reactive protein, the metabolic syndrome, and risk of incident of cardiovascular events. Circulation 2003;107:391-397.
12. Grundy SM, Brewer HB, Cleeman JI et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109:433-438.
13. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001; 44:929-945.
14. Stratton I, Adler AI, Andrew H et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-412.
15. NCEP Expert Panel on Detection, Evaluation and Treatment of High Blood Pressure in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection and evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
16. Julius S. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-2031.
17. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003;362:759-766.